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Clinical factors affecting gefitinib treatment - one institution’s 
experience
Minato, Koichi1 Yoshino, Reiko1 Ishihara, Shin-Ichi2 
1 Gunma Cancer Center, Ota, Japan 2 Isesaki Municipal Hospital, 
Isesaki, Japan 
Purpose: To identify the clinical factors affecting the effectiveness on 
prognosis of advanced non-small-cell lung cancer patients treated with 
geﬁtinib in a practical setting.
Methods: Between August 2002 and December 2004, 80 advanced 
non-small-cell lung cancer patients were treated with geﬁtinib in 
Gunma Prefectural Cancer Center. We retrospectively analysed the 
relationship between clinical factors and response or overall survival. 
The clinical factors included the following: sex, age, smoking status, 
histologic subtype, dermatological toxicity, performance status, and 
treatment status.
Results: The overall response rate was 11.3% (9/80). The response rate 
for adenocarcinoma was 14.8% (8/54) and that for non-adenocarcino-
ma was 3.8% (1/26)(p=.282). In terms of smoking status, the response 
rate of smokers was 4.1% (2/49) and that of non-smokers was 21.4% 
(6/28)(p=.051). The response rate of males was 9.1% (5/55) and that 
of females was 16.0% (4/25)(p=.485). The median overall survival of 
all patients was 8.9 months. Median survival (MS) of females was 15.9 
months, that of males was 6.8 months (p=0.015). As for smoing status, 
the MS of smokers was 6.9 months and that of non-smokers was 15.9 
months (p=0.003). The MS of the patients with skin toxicity was 14.0 
months and for those without skin toxicity was 5.9 months (p=0.0001). 
Good PS patients showed longer suivival compared to the poor PS 
patients (p=0.0002).
Conclusion: Signiﬁcantly longer survival was observed in females, 
non-smokers, PS 0-1and with occurrence of skin toxicity.
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Background: PS 2 or 3 patients are usually excluded from clinical 
trials. Optimal treatment in this setting remains a matter of controversy. 
The aim of this study by Intergroupe Francophone de Cancerologie 
Thoracique (IFCT) was to evaluate 3 monotherapy modalities and bet-
ter understand causes for compromised PS.
Methods: PS 2 or 3 patients with conﬁrmed advanced NSCLC were 
included into a multicenter phase II randomized trial: arm A, geﬁtinib 
(250 mg/day), arm B gemcitabine (1250 mg/m≥, day 1 & 8, every 3 
weeks) and arm C docetaxel (75 mg/m≥, day 1, every 3 weeks). Treat-
ments were maintained until progression or unacceptable toxicity. The 
second-line treatment consisted of: arm A: docetaxel (75 mg/m≥, day 
1, every 3 weeks) and arm B/C: geﬁtinib (250 mg/day). The primary 
endpoint was Progression Free Survival (PFS).
Results: Between December 2004 and February 2007, 117 patients 
were enrolled. Out of the 100 ﬁrst eligible patients, the characteris-
tics were the following: median age 71 years (range 30-79), male 84 
% - female 16 %, PS=2 72 %, PS=3 28 %, adenocarcinoma 52 %, 
squamous cell 25 %, other 23 %. No objective signiﬁcant difference 
could be observed between PS 2 and 3, among clinical and biological 
parameters (table). 35% of PS 2 patients versus 16 % of PS 3 patients 
received a second-line treatment (as deﬁned in the protocol, p=0.12). 
4 fatal events were related to treatment: 3 related to chemotherapy 
attributed to febrile neutropenia and 1 related to geﬁtinib attributed to 
bowel obstruction.
Conclusions: In this study neither comorbidities nor the tumour burden 
could explain the difference observed in the PS. This preliminary anal-
ysis suggests that PS doesn’t seem to have any clinical impact in the 
number of given second-line treatments. The complete results of PFS, 
overall survival and toxicity by arm will be presented at the meeting.
Characteristics TOTAL (n=100) PS 2 (n=72) PS 3 (n=28) p
PATIENT
Age (years) 71 (30-79) 71.5 (30-79) 68.5 (48-79) 0.2
Female 16 13 (18 %) 3 (11 %) 0.58
Charlson Score (range) 1 (0-6) 1 (0-5) 1 (0-6) NS
Haemoglobin (g/dL) 11.7 12.1 11.2 0.09
LDH (IU/L) 406 406 388 0.66
TUMOR BURDEN
Adenocarcinoma 52 37 (51 %) 15 (54 %) 0.96
Stage IV 80 57 (79 %) 23 (82 %) 0.95
Metastatic sites (2+) 27 19 (26 %) 8 (29 %) 0.96
Initial RECIST (mm) 88.5 89.5 78.5 0.62
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Dual retinoid agonists with chemotherapy in advanced non-small-
cell lung cancer
Nandan, Raghu 
Lakewood, CA, USA
Non-small-cell lung cancer (NSCLC) is the most common cause of 
cancer deaths in both women and men. Most patients are diagnosed 
at an advanced stage and have very poor outcomes; better treatments 
are urgently needed. The efﬁcacy of chemotherapy is usually limited; 
therefore several non-cytotoxic targeted therapy agents have been 
recently evaluated, either alone or in combination with chemotherapy. 
Both tretinoin, a retinoic acid receptor (RAR) agonist as well as bex-
arotene (a rexinoid receptor (RXR) agonist have been used in non small 
cell lung cancer both alone and in combination with chemotherapy with 
activity. Also, both have reduced bioavailability with continued dosing. 
Our earlier study with intermittent dosing of tretinoin and chemothera-
py showed activity. This is a preliminary report on the combination of 
brief periods of tretinoin and bexarotene in combination with cisplatin 
and docetaxel based chemotherapy in 12 patients advanced non small 
cell lung cancer. 
The ECOG performance status was 2 in nine patients and 1 in three. 
Four (33%) patients had brain metastases controlled with radiation. 
Nine patients were previously untreated for NSCLC and three had been 
treated with a tyrosine kinase inhibitor before this regimen. 11 patients 
had stage IV disease and one had IIIb disease. 7 were females, 5 were 
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males. There were 7 with adenocarcinoma, 3 squamous cell cancer, 1 
with large cell and 1 with poorly differentiated non small cell cancer. 
One of the 12 patients had assessable but no measurable disease. 
Eight patients (66%) achieved a partial response, one achieved a minor 
response, two had stable disease, and one had progressive disease in 
one site with tumor regression in all other sites. Median survival was 
16.5 months and 5 patients are still being followed. The number of 
cycles was 1-6, median of 3. There was 1 case of grade 4 thrombocy-
topenia without bleeding, 2 cases of line related sepsis; 2 patients with 
neutropenic infection, 2 patients with DVT (1 related to central line) 
and 1 of peripheral neuropathy related to Taxotere requiring discontinu-
ation; 1 patient had a bleeding peptic ulcer successfully treated. There 
was no evidence of skin rashes, headaches, unexplained leukocytosis or 
other ﬁndings suggestive of retinoic acid syndrome. There was no case 
of pancreatitis. No dose modiﬁcation of the retinoids was needed. 
The combination of brief periods of RAR and RXR agonists given 
together, along with chemotherapy appears to produce promising 
responses and survival in this group of patients. The brief period of 
administration of both agents may limit side effects reported with reti-
noids. This raises the hypothesis that the high response rate observed 
is due to increased anti-tumor activity through cross-talk and heterodi-
merization of the RAR and RXR receptors. A follow up trial has been 
initiated. 
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Response rates of erlotinib or gefitinib compared to docetaxel as 
subsequent line therapy in advanced non-small cell lung cancer 
(NSCLC) in clinical practice
Ng, Raymond C.; Loreto, Michael; Lee, Roy; Leighl, Natasha B.; 
Princess Margaret Hospital, Toronto, ON, Canada
Background: In randomized trials, docetaxel has been shown to have 
activity as second-line therapy in advanced NSCLC; and erlotinib in 
the third-line setting after failure of ﬁrst-line platinum-based chemo-
therapy. The role of epidermal growth factor receptor tyrosine kinase 
inhibitors (EGFRTKI) as second-line treatment prior to docetaxel 
chemotherapy remains ill deﬁned and is currently the subject of several 
ongoing trials. Here we explore the outcomes of these agents’ uses in 
clinical practice. 
Method: A retrospective review of the NSCLC database at Princess 
Margaret Hospital in Toronto, Canada was undertaken. Patients who 
have previously received docetaxel after failure of platinum-based 
chemotherapy were identiﬁed and a chart review was undertaken to 
further identify those who also received erlotinib or geﬁtinib to assess 
the clinical beneﬁt of these drugs. The primary outcome assessed was 
response rate and secondary outcomes were time to progression and 
survival.
Results: 77 patients received docetaxel for advanced NSCLC from 
2001 to Dec 2006. Of these, 55 (71%) were administered as second-
line treatment following failure of platinum-based chemotherapy, 20 
(26%) received it in the third-line setting and two (3%) as fourth-line 
treatment (see Table 1). Assessable response rates to second line 
docetaxel were partial response (PR) of 4%, stable disease (SD) of 47% 
and progressive disease (PD) in 49%. Of these 55 patients, 26 subse-
quently went to receive an EGFRTKI. Assessable response rates in 
these patients to third-line EGFRTKI were CR in 4% (1/23), PR in 9% 
(2/23), SD in 26% (6/23) and PD in 61% (14/23). Three patients were 
not assessable for response due to death and withdrawal from medica-
tion prior to assessment.
In the 20 patients who received docetaxel in the third line setting, 17 
received prior EGFRTKI therapy. Response rates to an EGFRTKI in 
second line were PR of 12% (2/17), SD of 6% (1/17) and PD of 82% 
(14/17) while responses to third-line docetaxel were PR of 8% (1/13), 
SD of 69% (9/13) and PD of 23% (3/13). Seven were not assessable for 
response due to death or withdrawal prior to assessment.
Updated data on demographics and secondary outcomes will be pre-
sented at the meeting.
Conclusions: In this retrospective non-randomized review of patients 
with advanced NSCLC who progressed following ﬁrst-line platinum-
based chemotherapy, the use of an EGFRTKI as second-line therapy 
did not appear to be superior to when it is administered in the third-line 
setting following docetaxel chemotherapy. However, this may be con-
founded by selection bias. Randomized studies are required to directly 
test this hypothesis.
Table1. Response rates of EGFRTKI and docetaxel in 2nd and 3rd line setting
 CR PR SD PD
2nd line therapy 
EGFRTKI 0% 12% 6% 82%
Docetaxel 0% 4% 47% 49%
3rd line therapy
EGFRTKI 4% 9% 26% 61%
Docetaxel 0% 8% 69% 23%
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Phase II study of gefitinib as a first-line therapy in elderly patients 
with lung adenocarcinoma (WJTOG 0402-DI)
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Background: Elderly patients with advanced non-small-cell lung 
cancer (NSCLC) are often unsuitable for platinum-based chemo-
therapy due to comorbidity. Monotherapy, for example docetaxel, is the 
preferred treatment for elderly patients (Kudoh. J Clin Oncol 2006). 
EGFR tyrosine kinase inhibitors, such as geﬁtinib and erlotinib, show 
remarkable responses in some patients with NSCLC. Adenocarcinoma 
histology and Asian origin are predictors of these responses. Therefore, 
we conducted a phase II study of geﬁtinib as a ﬁrst-line therapy in 
elderly patients with lung adenocarcinoma in Japan.
Methods: Eligible patients with stage IIIB/IV lung adenocarcinoma 
were 70 years or older, chemotherapy-naïve, and had a performance 
status of 2 or lower. Patients with interstitial pneumonitis that was 
detectable on a chest computed tomogram were ineligible. Eligible 
